Cycloastragenol reduces microglial NLRP3 inflammasome activation in Parkinson's disease models by promoting autophagy and reducing Scrib-driven ROS.

Phytomedicine

Department of Neurology, Center for Cognitive Neurology, Fujian Medical University Union Hospital, 29 Xinquan Road, Fuzhou 350001, China; Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, 29 Xinquan Road, Fuzhou 350001, China; Institute of Clinical Neurology, Fujian Medical University, 29 Xinquan Road, Fuzhou 350001, China; Fujian Key Laboratory of Molecular Neurology and Institute of Neuroscience, Fujian Medical University, 88 Jiaotong Road, Fuzhou 350001, China; Clinical Research Center for Precision Diagnosis and Treatment of Neurological Diseases of Fujian Province, Fuzhou 350001, China. Electronic address:

Published: December 2024

AI Article Synopsis

  • In Parkinson's disease (PD), microglia play a key role in maintaining cell health, and cycloastragenol (CAG) has potential neuroprotective effects by reducing inflammation.
  • This study aimed to investigate CAG's impact on microglial inflammasome activation and its mechanisms in PD treatment using mouse models and various laboratory techniques.
  • Results showed that CAG decreased neuroinflammation by promoting autophagy and reducing harmful reactive oxygen species, thus improving neuron health and behavior in PD mice, highlighting its therapeutic promise.

Article Abstract

Background: In Parkinson's disease (PD), microglial autophagy is crucial for the maintenance of cellular redox homeostasis. Meanwhile, cycloastragenol (CAG), a triterpenoid saponin and the principal active component of Astragalus, reduces the activation of NLRP3 inflammasomes. Nevertheless, the specific molecular mechanisms underlying the CAG-mitigated microglial neuroinflammation remains obscure in PD.

Purpose: This study explored the role of CAG in the activation of microglial NLRP3 inflammasome and the mechanisms underlying its therapeutic potential for PD treatment.

Study Design: The effect of CAG was assessed in α-Syn-induced primary microglia and PD models.

Methods: AAV1/2-hsyn-SNCA (A53T) was stereo-injected into the striatum of mice to induce PD models and CAG was orally administered. The mice underwent quantitative 4D proteomics analysis and behavioral assessments. The primary microglia and neuron cultures were analyzed by western blotting, immunofluorescence, transmission electron microscopy, etc. RESULTS: CAG reduced phagocytosis-induced reactive oxygen species (ROS) by suppressing the microglial Scribble (Scrib) and p22 expression. Concurrently, CAG enhanced autophagy, promoted α-Syn clearance, and reduced mitochondrial damage. These synergistic effects downregulated NLRP3 inflammasome activation, in turn reducing gasdermin D cleavage, caspase-1 activation, and the release of interleukin-1β and interleukin-18. Further investigation revealed that CAG shielded neurons from α-Syn toxicity, thus attenuating behavioral impairments observed in the mouse PD model.

Conclusion: CAG mitigates neuroinflammation by inhibiting ROS-induced NLRP3 inflammasome activation in microglia via promoting microglial autophagy and reducing the activity of Scrib-associated nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, which signifies a promising alternative approach to PD management.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phymed.2024.156210DOI Listing

Publication Analysis

Top Keywords

nlrp3 inflammasome
16
inflammasome activation
12
microglial nlrp3
8
parkinson's disease
8
autophagy reducing
8
microglial autophagy
8
cag
8
mechanisms underlying
8
primary microglia
8
microglial
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!